FindTrial
Sign In

Odevixibat

DRUG5 trials

Sponsors

Albireo, an Ipsen Company, Albireo

Conditions

Alagille SyndromeBiliary AtresiaProgressive Familial Intrahepatic Cholestasis

Phase 3

Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
CompletedNCT04336722
Albireo, an Ipsen CompanyBiliary Atresia
Start: 2020-07-08End: 2026-06-22Updated: 2026-07-02
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
CompletedNCT04674761
AlbireoAlagille Syndrome
Start: 2021-03-19End: 2022-09-09Updated: 2023-11-02
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
Active, not recruitingNCT05035030
Albireo, an Ipsen CompanyAlagille Syndrome
Start: 2021-09-03End: 2026-12-31Updated: 2026-08-31
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
Active, not recruitingNCT05426733
Albireo, an Ipsen CompanyBiliary Atresia
Start: 2022-07-05End: 2026-10-28Target: 180Updated: 2026-08-31

Unknown Phase

Odevixibat for the Treatment of Progressive Familial Intrahepatic Cholestasis
NCT04483531
AlbireoProgressive Familial Intrahepatic Cholestasis
Updated: 2026-07-23

Related Papers

Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
2024-04-2322 citations
Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis.
2022-09-069 citations